Connect with us

Industry News

Medical Marijuana Market To Reach USD 148.35 Billion By 2026 | Reports And Data

Avatar

Published

on

default_cannabis_industry_cannamaps

Medical application of marijuana as pain management in cancer, seizures, neurology, and muscle spasm will drive the market growth.
Market Size – USD 11.70 Billion in 2018, Market Growth – CAGR of 26.4%, Market Trends – Legalization of marijuana in several countries.NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) — The Global Medical Marijuana Market is forecast to reach USD 148.35 Billion by 2026, according to a new report by Reports and Data.  Marijuana is used for treating chronic pain that affects millions of people each year across the globe, thus increasing the demand for the product as a treatment procedure for medical conditions. Statistically, around 25 million people endure acute pain in the US. Moreover, several countries around the globe have made medical marijuana legal, i.e., it would allow people to use marijuana for health purposes; therefore, boosting the market for the medical marijuana market.Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1413Side effects of the products include dizziness, fatigue, speech problem, constipation, and insomnia will hamper the growth of the market. Additionally, lack of data safety and problem in undertaking medical marijuana business is also estimated to hinder the growth of the market.North America dominates the market of medical marijuana. The major contributors are the US and Canada. As of 2018, 30 U.S. states have permitted the application of medical marijuana. Moreover, the growing number of research studies in the US, encouraging and supporting marijuana’s use for medical purposes will supplement the North American medical marijuana market growth.In 2017, Oxford University went into a partnership with Kingsley Capital Partners, for the development of cannabis treatment for inflammatory and cancer diseases. These partnerships are expected to have a positive impact on the market of medical marijuana.Further key findings from the report suggestCountries are beginning to liberalize laws related to medical marijuana; the market is forecasted to witness a surge in demand. Statistically, the majority of the cannabis, are currently, sold through illicit channels.Several countries have recognized the advantages of this product and are in the process of legalizing it.With a rise in the volume of clinical trials and scientific studies, the demand for cannabis for clinical use is forecasted to grow over the forecast period. Medical marijuana held a market share of 53% in the year 2018.Countries in North America have also started promoting derivatives such as oils, tinctures, and resins, along with products like vaporizers, among millennials who are considered primary consumers.The oil segment is forecasted to grow with the highest CAGR of 27.1% in the forecast period. Hemp oil is in high demand among healthcare sector for clinical purposes.Health concerns associated with smoking is another factor that stops doctors from prescribing it. Hence, oil or edible forms of marijuana are generally prescribed and are growing in demand.On the basis of application, the market is segmented into Chronic Pain, Mental Disorders, Anorexia, Seizures, Muscle Spasm, Cancer, and Others.Chronic pain dominated the market, with a share of 63% in the year 2018. Marijuana reduced pain and also improved the quality of life among patients.On the basis of the route of administration, inhalation segment is forecasted to have the highest market share of 54% in the year 2026.Inhalation provides an advantage of controlled dosage and effective absorption of cannabinoids into the body. This should increase the demand for inhalation marijuana over the coming years.Dispensaries held a market share of 48% in the year 2018. These pharmacies sell various legal cannabis products in the form of tablets, vaporizers, balms, elixirs, and tinctures.Patients usually prefer buying medical products from authorized and legal sources to abide by the government’s rules, thus maximizing the revenue by this segment.Europe is forecasted to have a market share of 28% in the year 2026. Germany is the largest market for cannabis and thereby fuels the growth of the market in this region.Key participants Canopy Growth Corporation, Aphria, Inc., Aurora Cannabis, Maricann Group, Inc., Tilray, Cronos Group, Organigram Holdings, Inc., ABcann Medicinals, Inc., Tikun Olam, Insys Therapeutics, Inc., The Peace Naturals Project, MedReleaf Corporation, and GW Pharmaceuticals PLC.To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/medical-marijuana-marketSegments covered in the report:For the purpose of this report, Reports and Data have segmented the global Medical Marijuana Market on the basis of Marijuana Type, Product Type, Route of Administration, Distribution Channel, Medical Application, and Region:                      Marijuana Type Outlook (Revenue, USD Billion; 2016-2026)Medical MarijuanaRecreational MarijuanaProduct Type Outlook (Revenue, USD Billion; 2016-2026)OilBudsTincturesMedical Application Outlook (Revenue, USD Billion; 2016-2026)Chronic PainMental DisordersAnorexiaSeizuresMuscle SpasmCancerOthersRoute of Administration Outlook (Revenue, USD Billion; 2016-2026)InhalationOralIntravenousTopicalDistribution Channel Outlook (Revenue, USD Billion; 2016-2026)DispensariesOnlineOrder Now: https://www.reportsanddata.com/checkout-form/1413Regional Outlook (Revenue, USD Million; 2016-2026)North AmericaU.S.EuropeUKFranceAsia PacificChinaIndiaJapanMEALatin AmericaBrazilBrowse more reports of Pharmaceutical category at:  https://www.reportsanddata.com/report/category/pharma-and-healthcareAbout Reports and DataReports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.Contact Us:John WatsonHead of Business DevelopmentReports And Data | Web: www.reportsanddata.comDirect Line: +1-800-819-3052E-mail: sales@reportsanddata.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/05/20/1829108/0/en/Medical-Marijuana-Market-To-Reach-USD-148-35-Billion-By-2026-Reports-And-Data.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

AsiaBaseMetals Inc. Provides Additional Information Regarding Previously Announced Cooperation Agreement

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) — AsiaBaseMetals Inc. (the “Company”) (TSX-V: “ABZ”) wishes to provide additional information regarding the cooperation agreement (the “Agreement“) between the Company and a city (the “City“) within a member country (the “Country“) of the European Union (“EU“), as previously announced on June 19, 2019.
The Agreement provides for the City to apply for a licence for growing and selling cannabis for medical purposes (“Medical-Cannabis-Permit“) and, if it becomes permitted by law in the Country, a licence for the growing, processing and sale of cannabis for commercial purposes including recreational purposes (“Recreational-Cannabis-Permit“), through a limited liability company to be incorporated by the City (“City-New-Sub-Co-Ltd.“).  Upon City-New-Sub-Co-Ltd. obtaining a Medical-Cannabis-Permit or a Recreational-Cannabis-Permit, the City has agreed to transfer all or a majority of the shares of City-New-Sub-Co-Ltd. to the Company for a purchase price of up to approximately C$8,000 based on the current exchange rate.The City has informed the Company that it has commenced the process to incorporate City-New-Sub-Co-Ltd.The Company has spent approximately C$10,000 to date in regard to the Agreement, excluding legal fees, and has no financial obligations under the Agreement unless and until the Company acquires City-New-Sub-Co-Ltd. as noted above.  The Company is using its working capital to evaluate and pursue this and other mining and non-mining opportunities.There is no defined timeline for obtaining a Medical-Cannabis-Permit or Recreational-Cannabis-Permit and, unlike in Canada, completing the construction of a production facility is not required in order to apply for a Medical-Cannabis-Permit in the Country.  The Company has not designed or estimated costs to build a production facility or made a decision to build a production facility. For more information on the Agreement and the transactions contemplated therein, see the Company’s news release disseminated on June 19, 2019, a copy of which can be found on the Company’s profile on www.sedar.com.  Any transaction will be subject to receipt of regulatory approvals, including approval of the TSX Venture Exchange.For more information please email info@asiabasemetals.com.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Note Regarding Forward-Looking Statements: Certain disclosure in this release, including statements regarding the Agreement, the transactions contemplated thereby and the Company’s pursuit of opportunities, may constitute “forward-looking information” within the meaning of Canadian securities legislation. In making the forward-looking statements in this release, the Company has applied certain factors and assumptions that the Company believes are reasonable, including that the Company will obtain the necessary regulatory approvals for the transactions contemplated by the Agreement, the Medical-Cannabis-Permit will be obtained, the acquisition of City-New-Sub-Co-Ltd. by the Company will be completed as expected and will have the benefits expected by management. However, the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such uncertainties and risks include, among others, financing risks, delays in obtaining or inability to obtain required regulatory approvals, the Medical-Cannabis-Permit will not be obtained, the Company will not be able to use the working capital to pay associated costs with the Agreement or Medical-Cannabis Permit, as applicable, the acquisition of City-New-Sub-Co-Ltd. by the Company will not be completed as expected or will not have the benefits expected by management and changes in the Company’s plans. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.  There can be no assurance that the transaction contemplated by the Agreement will complete on the anticipated terms or at all.Contact Information

AsiaBaseMetals Inc.
Raj Chowdhry, Chief Executive Officer
Email:

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874839/0/en/AsiaBaseMetals-Inc-Provides-Additional-Information-Regarding-Previously-Announced-Cooperation-Agreement.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

American Herbal Products Association Hosts Inaugural Hemp-CBD Dietary Supplement Congress in Denver on August 15-16

Avatar

Published

on

default_cannabis_industry_cannamaps

Denver, CO, June 26, 2019 (GLOBE NEWSWIRE) —The American Herbal Products Association (AHPA) is presenting a unique, two-day Hemp-CBD Supplement Congress in Denver this August to provide critical input for companies navigating the rapidly evolving legal, regulatory and financial landscapes to manufacture and market dietary supplement products with hemp or hemp-derived ingredients including cannabidiol (CBD). The event features presentations from Federal officials, including speakers from the FDA and USDA who will provide insights into their agencies’ approach to regulating hemp-CBD and supplements made with these ingredients. According to the latest research, hemp-CBD sales are projected to surpass $15 – 20 billion in the U.S. by 2024, indicating an immediate need for manufacturers and retailers to understand the role of hemp in the dietary supplement category. “The U.S. market for hemp-derived CBD in dietary supplements is growing and evolving rapidly and companies that manufacture and sell CBD supplements face a host of challenges and opportunities. AHPA’s Congress will provide companies with the information needed to successfully navigate challenges and take advantage of opportunities,” explains AHPA President Michael McGuffin. “FDA and USDA officials will join legal and industry experts to provide compliance strategies for dietary supplement regulatory requirements to help companies meet the growing consumer demand for high-quality, safe products.”AHPA’s Hemp-CBD Congress features a full-day of presentations and discussions on Friday, August 16 and two, half-day workshops on Thursday, August 15 that will cover:How to comply with FDA’s current good manufacturing practice (cGMP) requirements for dietary supplements – training by EAS Consulting Group.New dietary ingredient (NDI) notifications and generally recognized as safe (GRAS) for hemp as a food additive and dietary ingredient – presented by AIBMR Life SciencesIndustry experts and government officials will present on a host of issues impacting Hemp-CBD companies, including:Getting to Market: Hemp Supply Chain ManagementOvercoming Regulatory Obstacles: Updates from the FDA, USDA and Individual StatesPrimer on FDA Regulation of Hemp-CBD SupplementsThe Hemp-CBD Supplement Market: A Financial SnapshotHemp-CBD Supplements from the Retailers’ PerspectiveNotable sessions include a presentation from USDA Agricultural Marketing Service (AMS) senior marketing specialist William Richmond, who will provide an update on USDA efforts related to the recent decriminalization of hemp. In addition, the FDA will provide an update on the agency’s ongoing efforts to design and implement a regulatory framework to ensure informed access to safe, legal products. This session is sponsored by Greenspoon Marder LLP and will be moderated by Jessica Wasserman, a partner in the International, Government Relations and Cannabis Law practice.USDA Speaker Bio – Bill RichmondBill Richmond leads the USDA, Agricultural Marketing Service, Specialty Crops Program in Washington, D.C. and is responsible for establishment and implementation of the U.S. Domestic Hemp Production Program. In this role, he is responsible for rulemaking, public education, and stakeholder outreach. In prior roles, Bill was the Acting Director of the USDA team responsible for establishing new labeling rules for bioengineered (GMO) foods in the U.S., served as the Chief of Staff of the Agricultural Marketing Service from 2016-2018, and led the Colorado dairy field office. Event DetailsWhere: Crowne Plaza Denver, 1450 Glenarm Pl, Denver, CO 80202When: Thursday, August, 15 & Friday, August, 16, 2019Register for the Congress: http://bit.ly/HempCBDCongressBecome a Sponsor PartnerYour tax-deductible sponsorship of AHPA’s Hemp-CBD Supplement Congress supports the important work of the American Herbal Products Association. Sponsors will be recognized in all marketing materials, PR and onsite throughout the event. For information on individual and corporate sponsorships, contact Amber Bennett at abennett@ahpa.org.About AHPAThe American Herbal Products Association (AHPA) is the national trade association and voice of the herbal products industry. AHPA is comprised of more than 400 member companies, consisting primarily of domestic and foreign companies doing business as growers, processors, manufacturers and marketers of herbs and herbal products as foods, dietary supplements, cosmetics, and non-prescription drugs, and also including companies that provide expert services to the herbal trade. Founded in 1982, AHPA’s mission is to promote the responsible commerce of herbal products to ensure that consumers continue to enjoy informed access to a wide variety of herbal goods. www.AHPA.orgMedia and Press Pass ContactSteve Hoffman, Compass Natural — steve@compassnaturalmarketing.com — (303) 807-1042# # #AttachmentsWilliam Bill Richmond USDA SMALLHemp-CBD Congress Sponsors verticalHaley Chitty (media inquires)
American Herbal Products Association (AHPA)
301-588-1171 x104
communications@ahpa.org

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874682/0/en/American-Herbal-Products-Association-Hosts-Inaugural-Hemp-CBD-Dietary-Supplement-Congress-in-Denver-on-August-15-16.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

EnWave and Aurora Cannabis Expand Scope of Machine Delivery to Achieve Good Manufacturing Practice (GMP) Standards

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (NYSE: ACB), is expanding the scope of requirements for its potential purchase of a third 120kW Radiant Energy Vacuum (“REV™”) machine targeted for its European operations in Denmark. Aurora Nordic Cannabis, a subsidiary of Aurora, plans to develop a pharmaceutical-level GMP facility, which requires several upgrades to the contemplated machinery.  These upgrades will be confirmed as soon as possible and will also increase the economic profile of this prospective equipment purchase.
On April 26, 2019, EnWave and Aurora announced that the companies had entered into a royalty-bearing commercial license agreement with sub-licensing rights, providing Aurora with the exclusive rights to EnWave’s patented REV™ drying technology for the production of cannabis materials in the European Union, excluding Portugal (the “European License”).Aurora intends to pursue widespread adoption of the REV™ technology throughout its global operations to capture the significant advantages of EnWave’s drying technology when compared to traditional drying methods. Benefits of REV™ Technology in the Cannabis IndustryEnWave’s patented REV™ technology is a rapid, low temperature, continuous drying method that maintains optimal terpene levels, flavour, as well as other product attributes during the drying process. The company’s vacuum-microwave technology enables fast, uniform drying with flexible final moisture content; capabilities that are unattainable with freeze drying or air drying.In the cannabis industry, REV™ technology provides for capital expenditure savings on drying space (smaller footprint) and related HVAC investments, as well as the ability to free up space, which can be repurposed to increase the economic output of each facility.  Furthermore, EnWave’s REV™ technology reduces drying time from 5-7 days to less than two hours, resulting in significant working capital savings and speed to market of product. The technology has certain additional benefits, including the support of industrial scale flow-though, accelerating the ability for large-scale processing of cannabis and CBD-rich biomass into intermediate or finished product.About EnWaveEnWave Corporation, a Vancouver-based advanced technology company, has developed Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products. REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with industry leaders in multiple verticals for the use of REV™ technology. The company has signed over twenty royalty-bearing licenses to date, opening up nine distinct market sectors for commercialization of new and innovative products. In addition to these licenses, EnWave has formed a Limited Liability Corporation, NutraDried Food Company, LLC, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese® brand. EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour;powderREV® which is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point, andquantaREV® which is used for continuous, high-volume low-temperature drying.An additional platform, freezeREV®, is being developed as a new method to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.EnWave CorporationMr. Brent Charleton, CFA
President and CEO
For further information:Brent Charleton, CFA , President and CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net
Dan Henriques, CPA, Chief Financial Officer at +1 (604) 835-5212
E-mail: dhenriques@enwave.net  
Deborah Honig, Corporate Development at + 1 (647) 203-8793
E-mail: dhonig@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. No statement in this press release should be construed as a waiver of any party’s rights, and all such rights are reserved. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874676/0/en/EnWave-and-Aurora-Cannabis-Expand-Scope-of-Machine-Delivery-to-Achieve-Good-Manufacturing-Practice-GMP-Standards.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending